GlassScriptPhysician profile
Michael H Koo
NPI 1780847681
$23,950.51
in general payments reported to CMS, 2019-2025
54 companies · $14K in 2025
The $14K reported for 2025 was more than what 91% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,289 · 2020: $685 · 2021: $1,290 · 2022: $2,346 · 2023: $2,593 · 2024: $2,104 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $11K · Food and Beverage: $7,303.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $11,038.18 |
| Food and Beverage | $7,303.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $13,098.88 | 2021-2025 | Corevalve Evolut R, Symplicity G3, Onyx Frontier |
| Novartis Pharmaceuticals Corporation | $1,259.51 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $936.60 | 2019-2023 | Xarelto |
| Abbott Laboratories | $798.19 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Mitraclip, Navitor |
| Astrazeneca Pharmaceuticals LP | $724.93 | 2019-2025 | Farxiga, Wainua |
| Boston Scientific Corporation | $683.06 | 2019-2025 | Bodyguardian, Watchman Flx, Emerge Push |
| Amgen INC. | $629.18 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $579.57 | 2021-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $457.81 | 2019-2025 | Eliquis, Camzyos |
| Medtronic Vascular, INC. | $442.30 | 2019-2020 | |
| Pfizer INC. | $419.74 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $353.92 | 2019-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $290.35 | 2021-2025 | Jardiance |
| Abiomed | $266.53 | 2019-2025 | Impella |
| Sanofi-Aventis U.S. LLC | $259.85 | 2019-2023 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Koo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.